Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1–3
Open Access
Abstract
Introduction Nusinersen is used in spinal muscular atrophy (SMA) to improve peripheral muscle function; however, respiratory effects are largely unknown. Aim To assess the effects of nusinersen on respiratory function in paediatric SMA during first year of treatment. Methods A prospective observational study in paediatric patients with SMA who began receiving nusinersen in Queensland, Australia, from June 2018 to December 2019. Outcomes assessed were the age-appropriate respiratory investigations: spirometry, oscillometry, sniff nasal inspiratory pressure, mean inspiratory pressure, mean expiratory pressure, lung clearance index, as well as polysomnography (PSG) and muscle function testing. Lung function was collected retrospectively for up to 2 years prior to nusinersen initiation. Change in lung function was assessed using mixed effects linear regression models, while PSG and muscle function were compared using the Wilcoxon signed-rank test. Results Twenty-eight patients (15 male, aged 0.08–18.58 years) were enrolled: type 1 (n=7); type 2 (n=12); type 3 (n=9). The annual rate of decline in FVC z-score prior to nusinersen initiation was −0.58 (95% CI −0.75 to −0.41), and post initiation was −0.25 (95% CI −0.46 to −0.03), with a significant difference in rate of decline (0.33 (95% CI 0.02 to 0.66) (p=0.04)). Most lung function measures were largely unchanged in the year post nusinersen initiation. The total Apnoea–Hypopnoea Index (AHI) was reduced from a median of 5.5 events/hour (IQR 2.1–10.1) at initiation to 2.7 events/hour (IQR 0.7–5.3) after 1 year (p=0.02). All SMA type 1% and 75% of SMA types 2 and 3 had pre-defined peripheral muscle response to nusinersen. Conclusion The first year of nusinersen treatment saw reduced lung function decline (especially in type 2) and improvement in AHI.Keywords
Funding Information
- Biogen (Not applicable)
This publication has 38 references indexed in Scilit:
- Reference values for respiratory events in overnight polygraphy from infants aged 1 and 3monthsSleep Medicine, 2013
- Longitudinal course of lung function and respiratory muscle strength in spinal muscular atrophy type 2 and 3European Journal of Paediatric Neurology, 2013
- Observational Study of Spinal Muscular Atrophy Type 2 and 3Archives of Neurology, 2011
- Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)Pediatric Physical Therapy, 2011
- An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patientsNeuromuscular Disorders, 2007
- Sleep Disorders and Neuromuscular DiseaseSeminars in Neurology, 2005
- Sleep disordered breathing in spinal muscular atrophyNeuromuscular Disorders, 2004
- Natural History in Proximal Spinal Muscular AtrophyArchives of Neurology, 1995
- Pulmonary Function in Spinal Muscular AtrophyJournal of Child Neurology, 1994
- International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)Neuromuscular Disorders, 1992